Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
Trinity Biotech (Nasdaq: TRIB) has successfully regained compliance with two crucial Nasdaq listing requirements. The company has met the $1.00 per share minimum bid price requirement by maintaining a closing bid price at or above $1.00 for ten consecutive business days from August 12-25, 2025. Additionally, Trinity Biotech has satisfied the minimum market value of publicly held shares (MVPHS) requirement by maintaining an MVPHS of $15 million or greater for more than 10 consecutive business days.
This development resolves the compliance issues that arose on March 14, 2025, when the company received notices from Nasdaq regarding its failure to meet both requirements. While Trinity Biotech has regained compliance, the company acknowledges there is no assurance of maintaining these requirements in the future.
Trinity Biotech (Nasdaq: TRIB) ha nuovamente ottenuto la conformità a due requisiti fondamentali di quotazione al Nasdaq. La società ha rispettato il requisito del prezzo minimo per azione di $1,00, mantenendo un prezzo di chiusura pari o superiore a $1,00 per dieci giorni lavorativi consecutivi, dal 12 al 25 agosto 2025. Inoltre, Trinity Biotech ha soddisfatto il requisito del valore di mercato minimo delle azioni detenute dal pubblico (MVPHS), mantenendo un MVPHS pari o superiore a $15 milioni per oltre 10 giorni lavorativi consecutivi.
Questo sviluppo risolve le problematiche di conformità emerse il 14 marzo 2025, quando la società ha ricevuto notifiche dal Nasdaq per il mancato rispetto di entrambi i requisiti. Pur avendo ristabilito la conformità, la società precisa che non vi è certezza di poter mantenere tali requisiti in futuro.
Trinity Biotech (Nasdaq: TRIB) ha recuperado con éxito el cumplimiento de dos requisitos clave de cotización en Nasdaq. La compañía cumplió con el requisito del precio mínimo por acción de $1.00, manteniendo un precio de cierre igual o superior a $1.00 durante diez días hábiles consecutivos, del 12 al 25 de agosto de 2025. Además, Trinity Biotech satisface el requisito del valor de mercado mínimo de las acciones en manos del público (MVPHS), manteniendo un MVPHS de $15 millones o más por más de 10 días hábiles consecutivos.
Este avance resuelve los problemas de cumplimiento surgidos el 14 de marzo de 2025, cuando la compañía recibió notificaciones de Nasdaq por no cumplir ambos requisitos. Aunque Trinity Biotech ha recuperado el cumplimiento, reconoce que no hay garantía de mantener estos requisitos en el futuro.
Trinity Biotech(나스닥: TRIB)이 나스닥 상장 요건 중 두 가지 핵심 요건에 대한 적합성을 성공적으로 회복했습니다. 회사는 주당 최소 입찰가 $1.00 요건을 충족하여 2025년 8월 12일부터 25일까지 10거래일 연속으로 종가가 $1.00 이상을 유지했습니다. 또한 Trinity Biotech는 공개 보유주식의 최소 시가총액(MVPHS) 요건을 충족하여 MVPHS가 $1,500만 이상을 10거래일 이상 연속으로 유지했습니다.
이 조치는 회사가 두 요건을 충족하지 못해 나스닥으로부터 통지를 받은 2025년 3월 14일에 발생한 적합성 문제를 해결합니다. Trinity Biotech가 적합성을 회복했지만, 향후에도 이 요건들을 계속 유지할 것이라는 보장은 없음을 회사는 인정합니다.
Trinity Biotech (Nasdaq: TRIB) a retrouvé avec succès sa conformité à deux exigences clés de cotation au Nasdaq. La société a satisfait à l’exigence du prix d’offre minimum de 1,00 $ par action en conservant un cours de clôture d’au moins 1,00 $ pendant dix jours ouvrables consécutifs, du 12 au 25 août 2025. De plus, Trinity Biotech a rempli l’exigence de valeur de marché minimale des actions détenues par le public (MVPHS) en maintenant un MVPHS de 15 millions de dollars ou plus pendant plus de dix jours ouvrables consécutifs.
Cette évolution met fin aux problèmes de conformité survenus le 14 mars 2025, lorsque la société a reçu des avis du Nasdaq lui signalant le non-respect de ces deux exigences. Bien que Trinity Biotech ait retrouvé la conformité, la société reconnaît qu’il n’y a aucune assurance de pouvoir maintenir ces exigences à l’avenir.
Trinity Biotech (Nasdaq: TRIB) hat die Einhaltung von zwei wesentlichen Nasdaq-Listing-Anforderungen erfolgreich wiederhergestellt. Das Unternehmen erfüllte die Mindestgebotspreis-Anforderung von $1,00 pro Aktie, indem es einen Schlusskurs von mindestens $1,00 an zehn aufeinanderfolgenden Handelstagen vom 12. bis 25. August 2025 aufrechterhielt. Zusätzlich hat Trinity Biotech die Mindestanforderung an den Marktwert der öffentlich gehaltenen Aktien (MVPHS) erfüllt, indem ein MVPHS von $15 Millionen oder mehr für mehr als zehn aufeinanderfolgende Handelstage gehalten wurde.
Diese Entwicklung behebt die Compliance-Probleme, die am 14. März 2025 auftraten, als das Unternehmen von Nasdaq Mitteilungen über das Nicht-Erfüllen beider Anforderungen erhielt. Obwohl Trinity Biotech die Compliance wiedererlangt hat, weist das Unternehmen darauf hin, dass keine Garantie besteht, diese Anforderungen künftig aufrechterhalten zu können.
- Successfully regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share
- Met the minimum market value of publicly held shares (MVPHS) requirement of $15 million
- Maintained listing on Nasdaq Global Select Market
- No assurance of maintaining minimum bid price compliance in the future
- Previously failed to meet critical Nasdaq listing requirements
- Faces ongoing risks related to market acceptance and product development
Insights
Trinity Biotech successfully regained Nasdaq compliance, averting potential delisting risk and stabilizing its market presence.
Trinity Biotech has successfully regained compliance with two critical Nasdaq listing requirements that threatened its continued presence on the exchange. The company has satisfied the
This compliance resolution represents a significant stabilization for Trinity Biotech after receiving deficiency notices on March 14, 2025. Regaining compliance helps the company avoid the substantial negative consequences of a potential delisting, which typically include reduced liquidity, diminished investor confidence, restricted access to capital, and increased trading complexity.
While this development eliminates an immediate existential threat to Trinity's market position, the company appropriately cautions that maintaining future compliance isn't guaranteed. The wording "There can be no assurance, however, that the Company will be able to maintain compliance with the Minimum Bid Price Requirement in the future" signals continued underlying concerns about sustainable share price performance. For a biotechnology company focused on diagnostics and diabetes management, maintaining exchange listing requirements provides the market stability needed to focus on operational execution rather than existential market challenges.
DUBLIN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the
As previously reported, on March 14, 2025, the Company received a written notice from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s American Depositary Shares had closed below the
Additionally, as previously reported, on March 14, 2025, the Company also received notice from Nasdaq that the Company no longer met the requirement in Nasdaq Listing Rule 5450(b)(2)(C) that listed securities maintain a minimum market value of publicly held shares (“MVPHS”) of US
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.
| Contact: | Trinity Biotech plc | RedChip Companies Inc. |
| Susan O’Connor | Dave Gentry, CEO | |
| (353)-1-2769800 | (1)-407-644-4256 | |
| (1)-800-RED-CHIP (733-2447) | ||
| TRIB@redchip.com | ||
FAQ
What Nasdaq requirements did Trinity Biotech (TRIB) regain compliance with in 2025?
How long did Trinity Biotech (TRIB) maintain the required $1.00 share price to regain compliance?
When did Trinity Biotech (TRIB) receive the initial Nasdaq non-compliance notice?
What is the minimum market value of publicly held shares (MVPHS) requirement for Nasdaq?
Will Trinity Biotech (TRIB) maintain its Nasdaq listing going forward?
